hepatoАнналы хирургической гепатологииAnnaly khirurgicheskoy gepatologii = Annals of HPB Surgery1995-54642408-9524НЭИКОН ИСП10.16931/1995-5464.2025-1-31-38hepato-1189Research ArticleПЕЧЕНЬLIVERВнутрипеченочная холангиокарцинома: влияние гистологического подтипа на выживаемостьIntrahepatic cholangiocarcinoma: correlation between histological subtype and survivalhttps://orcid.org/0000-0003-0738-7642ЕфановМ. Г.EfanovM. G.

Ефанов Михаил Германович – доктор мед. наук, заведующий отделом гепатопанкреатобилиарной хирургии ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Mikhail G. Efanov – Doct. of Sci. (Med.), Head of the Hepatopancreatobiliary Surgery Department, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

m.efanov@mknc.ruhttps://orcid.org/0000-0003-0889-2720КарнауховН. С.KarnaukhovN. S.

Карнаухов Николай Сергеевич – канд. мед. наук, заведующий патологоанатомическим отделением ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Nikolai S. Karnaukhov – Cand. of Sci. (Med.), Head of the Pathology Department, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

nick07@bk.ruhttps://orcid.org/0000-0003-3286-1780БрицкаяН. Н.BritskaiaN. N.

Брицкая Наталья Николаевна – канд. мед. наук, соискатель ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Natalia N. Britskaia – Cand. of Sci. (Med.), Doctoral Candidate, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

britska_surg@mail.ruhttps://orcid.org/0000-0001-7990-3170МакаренкоН. В.MakarenkoN. V.

Макаренко Надежда Викторовна – научный сотрудник патологоанатомического отделения ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Nadezhda V. Makarenko – Researcher Associate of the Pathology Department, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

makarenko.pathologist@gmail.comhttps://orcid.org/0000-0002-8358-6603ТаракановП. В.TarakanovP. V.

Тараканов Павел Витальевич – канд. мед. наук, научный сотрудник отделения гепатопанкреатобилиарной хирургии ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Pavel V. Tarakanov – Cand. of Sci. (Med.), Researcher of the Hepatopancreatobiliary Surgery Department, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

p.tarakanov@mknc.ruhttps://orcid.org/0000-0001-8871-964XФисенкоД. В.FisenkoD. V.

Фисенко Денис Викторович – младший научный сотрудник отделения гепатопанкреатобилиарной хирургии ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Denis V. Fisenko – Junior Researcher of the Hepatopancreatobiliary Surgery Department, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

d.fisenko@mknc.ruhttps://orcid.org/0000-0001-5169-2199ЦвиркунВ. В.TsvirkunV. V.

Цвиркун Виктор Викторович – доктор мед. наук, профессор, главный научный сотрудник ГБУЗ “МКНЦ им. А.С. Логинова” ДЗ г. Москвы.

111123, Москва, шоссе Энтузиастов, д. 86

Victor V. Tsvirkun – Doct. of Sci. (Med.), Professor, Chief Researcher, Moscow Clinical Scientific Center named after A.S. Loginov.

86, Sh. Entuziastov, Moscow, 111123

tsvirkunvv@mail.ruГБУЗ “Московский клинический научный центр им. А.С. Логинова” Департамента здравоохранения г. МосквыРоссияMoscow Clinical Scientific Center named after A.S. LoginovRussian Federation2025280220253013138Copyright © Ефанов М.Г., Карнаухов Н.С., Брицкая Н.Н., Макаренко Н.В., Тараканов П.В., Фисенко Д.В., Цвиркун В.В., 20252025Ефанов М.Г., Карнаухов Н.С., Брицкая Н.Н., Макаренко Н.В., Тараканов П.В., Фисенко Д.В., Цвиркун В.В.Efanov M.G., Karnaukhov N.S., Britskaia N.N., Makarenko N.V., Tarakanov P.V., Fisenko D.V., Tsvirkun V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hepato.elpub.ru/jour/article/view/1189Цель

Цель. Изучить патогистологические подтипы внутрипеченочной холангиокарциномы и их влияние на выживаемость.

Материал и методы

Материал и методы. Анализировали периоперационные данные 65 пациентов с внутрипеченочной холангиокарциномой. У 32 (49%) больных выявлен гистологический подтип внутрипеченочной холангиокарциномы из мелких желчных протоков, у 33 (51%) диагностирован подтип из крупных желчных протоков.

Результаты

Результаты. Патогистологический подтип внутрипеченочной холангиокарциномы из крупных желчных протоков является значимым фактором, влияющим на общую выживаемость (р < 0,0001) и безрецидивную выживаемость (р = 0,0074).

Заключение

Заключение. В клинической практике оценка мелкопротокового и крупнопротокового подтипа внутрипеченочной холангиокарциномы является необходимой для стратификации факторов риска, влияющих на прогноз заболевания.

Aim

Aim. To study the pathological histological subtypes of intrahepatic cholangiocarcinoma and their impact on survival.

Materials and methods

Materials and methods. The study involved the analysis of perioperative data from 65 patients with intrahepatic cholangiocarcinoma. Among them, 32 patients (49%) were found to have the small bile duct subtype, while 33 patients (51%) were diagnosed with the large bile duct subtype.

Results

Results. The histopathological subtype of intrahepatic cholangiocarcinoma originating from large bile ducts is considered to be a significant factor affecting overall survival (p < 0.0001) and disease-free survival (p =0.0074).

Conclusion

Conclusion. In clinical practice, assessing the small and large duct subtypes of intrahepatic cholangiocarcinoma is claimed to be essential for stratifying risk factors affecting disease prognosis.

печеньжелчные протокивнутрипеченочная холангиокарциномагистологический подтипвыживаемостьliverbile ductsintrahepatic cholangiocarcinomahistological subtypesurvivalReferencesClements O., Eliahoo J., Kim J.U., Taylor-Robinson S.D., Khan S.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J. Hepatol. 2020; 72 (1): 95–103. https://doi.org/10.1016/j.jhep.2019.09.007Clements O., Eliahoo J., Kim J.U., Taylor-Robinson S.D., Khan S.A. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J. Hepatol. 2020; 72 (1): 95–103. https://doi.org/10.1016/j.jhep.2019.09.007Nakanuma Y., Sato Y., Harada K., Sasaki M., Xu J., Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J. Hepatol. 2010; 2 (12): 419–247. https://doi.org/10.4254/wjh.v2.i12.419Nakanuma Y., Sato Y., Harada K., Sasaki M., Xu J., Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J. Hepatol. 2010; 2 (12): 419–247. https://doi.org/10.4254/wjh.v2.i12.419Kendall T., Verheij J., Gaudio E., Evert M., Guido M., Goeppert B., Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl. 1: 7–18. https://doi.org/10.1111/liv.14093Kendall T., Verheij J., Gaudio E., Evert M., Guido M., Goeppert B., Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl. 1: 7–18. https://doi.org/10.1111/liv.14093Aishima S., Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J. Hepatobiliary Pancreat. Sci. 2015; 22 (2): 94–100. https://doi.org/10.1002/jhbp.154Aishima S., Oda Y. Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type. J. Hepatobiliary Pancreat. Sci. 2015; 22 (2): 94–100. https://doi.org/10.1002/jhbp.154Liau J.Y., Tsai J.H., Yuan R.H., Chang C.N., Lee H.J., Jeng Y.M. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod. Pathol. 2014; 27 (8): 1163–1173. https://doi.org/10.1038/modpathol.2013.241Liau J.Y., Tsai J.H., Yuan R.H., Chang C.N., Lee H.J., Jeng Y.M. Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features. Mod. Pathol. 2014; 27 (8): 1163–1173. https://doi.org/10.1038/modpathol.2013.241European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol. 2023; 79 (1): 181–208. https://doi.org/10.1016/j.jhep.2023.03.010European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol. 2023; 79 (1): 181–208. https://doi.org/10.1016/j.jhep.2023.03.010Kubo S., Shinkawa H., Asaoka Y., Ioka T., Igaki H., Izumi N., Itoi T., Unno M., Ohtsuka M., Okusaka T., Kadoya M., Kudo M., Kumada T., Kokudo N., Sakamoto M., Sakamoto Y., Sakurai H., Takayama T., Nakashima O., Nagata Y., Hatano E., Harada K., Murakami T., Yamamoto M. Liver Cancer Study Group of Japan Clinical Practice Guidelines for intrahepatic cholangiocarcinoma. Liver Cancer. 2022; 11 (4): 290–314. https://doi.org/10.1159/000522403Kubo S., Shinkawa H., Asaoka Y., Ioka T., Igaki H., Izumi N., Itoi T., Unno M., Ohtsuka M., Okusaka T., Kadoya M., Kudo M., Kumada T., Kokudo N., Sakamoto M., Sakamoto Y., Sakurai H., Takayama T., Nakashima O., Nagata Y., Hatano E., Harada K., Murakami T., Yamamoto M. Liver Cancer Study Group of Japan Clinical Practice Guidelines for intrahepatic cholangiocarcinoma. Liver Cancer. 2022; 11 (4): 290–314. https://doi.org/10.1159/000522403Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klümpen H.J., Malka D., Primrose J.N., Rimassa L., Stenzinger A., Valle J.W., Ducreux M.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023; 34 (2): 127–140. https://doi.org/10.1016/j.annonc.2022.10.506Vogel A., Bridgewater J., Edeline J., Kelley R.K., Klümpen H.J., Malka D., Primrose J.N., Rimassa L., Stenzinger A., Valle J.W., Ducreux M.; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023; 34 (2): 127–140. https://doi.org/10.1016/j.annonc.2022.10.506Abu Hilal M., Aldrighetti L., Dagher I., Edwin B., Troisi R.I., Alikhanov R., Aroori S., Belli G., Besselink M., Briceno J., Gayet B., D'Hondt M., Lesurtel M., Menon K., Lodge P., Rotellar F., Santoyo J., Scatton O., Soubrane O., Sutcliffe R., Van Dam R., White S., Halls M.C., Cipriani F., Van der Poel M., Ciria R., Barkhatov L., Gomez-Luque Y., Ocana-Garcia S., Cook A., Buell J., Clavien P.A., Dervenis C., Fusai G., Geller D., Lang H., Primrose J., Taylor M., Van Gulik T., Wakabayashi G., Asbun H., Cherqui D. The Southampton Consensus Guidelines for laparoscopic liver surgery: from indication to implementation. Ann. Surg. 2018; 268 (1): 11–18. https://doi.org/10.1097/SLA.0000000000002524Abu Hilal M., Aldrighetti L., Dagher I., Edwin B., Troisi R.I., Alikhanov R., Aroori S., Belli G., Besselink M., Briceno J., Gayet B., D'Hondt M., Lesurtel M., Menon K., Lodge P., Rotellar F., Santoyo J., Scatton O., Soubrane O., Sutcliffe R., Van Dam R., White S., Halls M.C., Cipriani F., Van der Poel M., Ciria R., Barkhatov L., Gomez-Luque Y., Ocana-Garcia S., Cook A., Buell J., Clavien P.A., Dervenis C., Fusai G., Geller D., Lang H., Primrose J., Taylor M., Van Gulik T., Wakabayashi G., Asbun H., Cherqui D. The Southampton Consensus Guidelines for laparoscopic liver surgery: from indication to implementation. Ann. Surg. 2018; 268 (1): 11–18. https://doi.org/10.1097/SLA.0000000000002524Бредер В.В., Базин И.С., Балахнин П.В., Виршке Э.Р., Косырев В.Ю., Ледин Е.В., Медведева Б.М., Моисеенко Ф.В., Мороз Е.А., Петкау В.В., Покатаев И.А. Практические рекомендации по лекарственному лечению больных злокачественными опухолями печени и желчевыводящей системы. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли. 2023; 13 (3s2): 494–538. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-494-538Breder V.V., Bazin I.S., Balakhnin P.V., Virshke E.R., Kosyrev V.Yu., Ledin E.V., Medvedeva B.M., Moiseenko F.V., Moroz E.A., Petkau V.V., Pokataev I.A. Practical recommendations for the drug treatment of patients with malignant tumors of the liver and biliary system. RUSSCO practical recommendations, part 1. Malignant tumors. 2023; 13 (3s2): 494–538. https://doi.org/10.18027/2224-5057-2023-13-3s2-1-494-538 (In Russian)Hayashi A., Misumi K., Shibahara J., Arita J., Sakamoto Y., Hasegawa K., Kokudo N., Fukayama M. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am. J. Surg. Pathol. 2016; 40 (8): 1021–1030. https://doi.org/10.1097/PAS.0000000000000670Hayashi A., Misumi K., Shibahara J., Arita J., Sakamoto Y., Hasegawa K., Kokudo N., Fukayama M. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am. J. Surg. Pathol. 2016; 40 (8): 1021–1030. https://doi.org/10.1097/PAS.0000000000000670Sigel C.S., Drill E., Zhou Y., Basturk O., Askan G., Pak L.M., Vakiani E., Wang T., Boerner T., Do R.K.G., Simpson A.L., Jarnagin W., Klimstra D.S. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am. J. Surg. Pathol. 2018; 42 (10): 1334–1345. https://doi.org/10.1097/PAS.0000000000001118Sigel C.S., Drill E., Zhou Y., Basturk O., Askan G., Pak L.M., Vakiani E., Wang T., Boerner T., Do R.K.G., Simpson A.L., Jarnagin W., Klimstra D.S. Intrahepatic cholangiocarcinomas have histologically and immunophenotypically distinct small and large duct patterns. Am. J. Surg. Pathol. 2018; 42 (10): 1334–1345. https://doi.org/10.1097/PAS.0000000000001118Chung T., Rhee H., Nahm J.H., Jeon Y., Yoo J.E., Kim Y.J., Han D.H., Park Y.N. Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. HPB (Oxford). 2020; 22 (6): 864–873. https://doi.org/10.1016/j.hpb.2019.10.009Chung T., Rhee H., Nahm J.H., Jeon Y., Yoo J.E., Kim Y.J., Han D.H., Park Y.N. Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. HPB (Oxford). 2020; 22 (6): 864–873. https://doi.org/10.1016/j.hpb.2019.10.009Kinzler M.N., Schulze F., Bankov K., Gretser S., Becker N., Leichner R., Stehle A., Abedin N., Trojan J., Zeuzem S., Schnitzbauer A.A., Wild P.J., Walter D. Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: results from a German tertiary center. Pathol. Res. Pract. 2022; 238: 154126. https://doi.org/10.1016/j.prp.2022.154126Kinzler M.N., Schulze F., Bankov K., Gretser S., Becker N., Leichner R., Stehle A., Abedin N., Trojan J., Zeuzem S., Schnitzbauer A.A., Wild P.J., Walter D. Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: results from a German tertiary center. Pathol. Res. Pract. 2022; 238: 154126. https://doi.org/10.1016/j.prp.2022.154126Gerber T.S., Müller L., Bartsch F., Gröger L.K., Schindeldecker M., Ridder D.A., Goeppert B., Möhler M., Dueber C., Lang H., Roth W., Kloeckner R., Straub B.K. Integrative analysis of intrahepatic cholangiocarcinoma subtypes for improved patient stratification: clinical, pathological, and radiological considerations. Cancers (Basel). 2022; 14 (13): 3156. https://doi.org/10.3390/cancers14133156Gerber T.S., Müller L., Bartsch F., Gröger L.K., Schindeldecker M., Ridder D.A., Goeppert B., Möhler M., Dueber C., Lang H., Roth W., Kloeckner R., Straub B.K. Integrative analysis of intrahepatic cholangiocarcinoma subtypes for improved patient stratification: clinical, pathological, and radiological considerations. Cancers (Basel). 2022; 14 (13): 3156. https://doi.org/10.3390/cancers14133156Zen Y. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities. Hum. Pathol. 2023; 132: 197–207. https://doi.org/10.1016/j.humpath.2022.06.001Zen Y. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities. Hum. Pathol. 2023; 132: 197–207. https://doi.org/10.1016/j.humpath.2022.06.001Guedj N. Pathology of cholangiocarcinomas. Curr. Oncol. 2022; 30 (1): 370–380. https://doi.org/10.3390/curroncol30010030Guedj N. Pathology of cholangiocarcinomas. Curr. Oncol. 2022; 30 (1): 370–380. https://doi.org/10.3390/curroncol30010030Banales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., Calvisi D.F., Perugorria M.J., Fabris L., Boulter L., Macias R.I.R., Gaudio E., Alvaro D., Gradilone S.A., Strazzabosco M., Marzioni M., Coulouarn C., Fouassier L., Raggi C., Invernizzi P., Mertens J.C., Moncsek A., Rizvi S., Heimbach J., Koerkamp B.G., Bruix J., Forner A., Bridgewater J., Valle J.W., Gores G.J. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (9): 557–588. https://doi.org/10.1038/s41575-020-0310-zBanales J.M., Marin J.J.G., Lamarca A., Rodrigues P.M., Khan S.A., Roberts L.R., Cardinale V., Carpino G., Andersen J.B., Braconi C., Calvisi D.F., Perugorria M.J., Fabris L., Boulter L., Macias R.I.R., Gaudio E., Alvaro D., Gradilone S.A., Strazzabosco M., Marzioni M., Coulouarn C., Fouassier L., Raggi C., Invernizzi P., Mertens J.C., Moncsek A., Rizvi S., Heimbach J., Koerkamp B.G., Bruix J., Forner A., Bridgewater J., Valle J.W., Gores G.J. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 2020; 17 (9): 557–588. https://doi.org/10.1038/s41575-020-0310-zAhn K.S., O'Brien D., Kang Y.N., Mounajjed T., Kim Y.H., Kim T.S., Kocher J.A., Allotey L.K., Borad M.J., Roberts L.R., Kang K.J. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach. Hepatol. Int. 2019; 13 (4): 490–500. https://doi.org/10.1007/s12072-019-09954-3Ahn K.S., O'Brien D., Kang Y.N., Mounajjed T., Kim Y.H., Kim T.S., Kocher J.A., Allotey L.K., Borad M.J., Roberts L.R., Kang K.J. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach. Hepatol. Int. 2019; 13 (4): 490–500. https://doi.org/10.1007/s12072-019-09954-3Ahn K.S., Kang K.J. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J. Hepatol. 2020; 12 (12): 1148–1157. https://doi.org/10.4254/wjh.v12.i12.1148Ahn K.S., Kang K.J. Molecular heterogeneity in intrahepatic cholangiocarcinoma. World J. Hepatol. 2020; 12 (12): 1148–1157. https://doi.org/10.4254/wjh.v12.i12.1148Andersen J.B., Spee B., Blechacz B.R., Avital I., Komuta M., Barbour A., Conner E.A., Gillen M.C., Roskams T., Roberts L.R., Factor V.M., Thorgeirsson S.S. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142 (4): 1021–1031.e15. https://doi.org/10.1053/j.gastro.2011.12.005Andersen J.B., Spee B., Blechacz B.R., Avital I., Komuta M., Barbour A., Conner E.A., Gillen M.C., Roskams T., Roberts L.R., Factor V.M., Thorgeirsson S.S. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142 (4): 1021–1031.e15. https://doi.org/10.1053/j.gastro.2011.12.005Ma B., Meng H., Tian Y., Wang Y., Song T., Zhang T., Wu Q., Cui Y., Li H., Zhang W., Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020; 20 (1): 318. https://doi.org/10.1186/s12885-020-06804-6Ma B., Meng H., Tian Y., Wang Y., Song T., Zhang T., Wu Q., Cui Y., Li H., Zhang W., Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer. 2020; 20 (1): 318. https://doi.org/10.1186/s12885-020-06804-6

The authors declare that there are no conflicts of interest present.